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OBJECTIVE— To assess the magnitude and independence of the effects of routine blood
pressure lowering and intensive glucose control on clinical outcomes in patients with long-
standing type 2 diabetes.
RESEARCHDESIGNANDMETHODS— This was a multicenter, factorial randomized
trial of perindopril-indapamide versus placebo (double-blind comparison) and intensive glucose
control with a gliclazide MR–based regimen (target A1C6.5%) versus standard glucose con-
trol (open comparison) in 11,140 participants with type 2 diabetes who participated in the
Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation
(ADVANCE) trial. Annual event rates and risks of major macrovascular and microvascular events
considered jointly and separately, renal events, and death during an average 4.3 years of fol-
low-up were assessed, using Cox proportional hazards models.
RESULTS— There was no interaction between the effects of routine blood pressure lowering
and intensive glucose control for any of the prespecified clinical outcomes (all P  0.1): the
separate effects of the two interventions for the renal outcomes and death appeared to be additive
on the log scale. Compared with neither intervention, combination treatment reduced the risk of
new or worsening nephropathy by 33% (95% CI 12–50%, P 0.005), new onset of macroalbu-
minuria by 54% (35–68%, P 0.0001), and new onset of microalbuminuria by 26% (17–34%).
Combination treatment was associated with an 18% reduction in the risk of all-cause death
(1–32%, P  0.04).
CONCLUSIONS— The effects of routine
blood pressure lowering and intensive glucose
control were independent of one another.
When combined, they produced additional
reductions in clinically relevant outcomes.
Diabetes Care 32:2068–2074, 2009
T ype 2 diabetes affects 240 millionpeople worldwide and significantlycontributes to the global burden of
vascular disease, of which both blood
pressure and glucose are important deter-
minants (1). Large-scale, randomized
controlled trials have clearly documented
the benefits of blood pressure–lowering
treatment on the risk of macrovascular
and microvascular complications and on
survival among patients with type 2 dia-
betes (2–4). Intensive glucose control has
been shown to reduce the risk of micro-
vascular complications (5–8), although it
did not improve patient survival or alter the
course of macrovascular complications in
the first 3–10 years (7–10). Current guide-
lines recommend a multifactorial approach
with simultaneous targeting of elevated
blood pressure and glucose levels in indi-
viduals with type 2 diabetes (11–13).
However, it is not known whether com-
bining blood pressure lowering and glu-
cose control can reduce the risk of
vascular complications to a greater extent
than either treatment alone.
Results from the UK Prospective Dia-
betes Study (UKPDS) have suggested that
the effects of blood pressure– and glu-
cose-lowering interventions might be ad-
ditive (14). In post hoc analyses, the
associations between vascular outcomes
and systolic blood pressure or A1C levels
achieved during follow-up were indepen-
dent, and there was a trend toward the
greatest benefit with the combination of
intensive blood pressure– and glucose-
lowering interventions (14). However,
because only a small subset of hyperten-
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sive subjects received both interventions,
the UKPDS had insufficient power to de-
termine conclusively whether the effects
of the treatments were additive in this
group or in the broader population with
type 2 diabetes. Moreover, the reported
excess mortality in the intensive glucose
control arm of the Action to Control Car-
diovascular Risk in Diabetes (ACCORD)
study compared with that for those ran-
domized to standard glucose control has
raised concerns about whether intensive
glucose lowering could modify or even
negate the benefits of blood pressure low-
ering in patients with type 2 diabetes (9).
Recently the Action in Diabetes and
Vascular Disease: Preterax and Diamicron
MR Controlled Evaluation (ADVANCE)
study, a large-scale, double-blind, ran-
domized factorial trial among 11,140
people with type 2 diabetes, demon-
strated the separate vascular benefits of
routine blood pressure lowering with a
fixed combination of perindopril and inda-
pamide after 4.3 years of follow-up and of
intensive glucose control, based on glicla-
zide MR, after 5 years of follow-up (4,8). In
this report, we present new analyses that
explore the extent to which blood pressure–
lowering treatment and intensive glucose
control provide independent and additive
benefits with respect to vascular outcomes
in patients with type 2 diabetes after 4.3
years of follow-up.
RESEARCH DESIGN AND
METHODS— ADVANCE was a facto-
rial randomized controlled trial evaluat-
ing the effects of blood pressure lowering
and intensive blood glucose control on
vascular outcomes. Detailed descriptions
of the study methods have been pub-
lished previously (4,8,15). In brief, a total
of 11,140 individuals with type 2 diabetes
aged 55 years, with a history of major
macrovascular or microvascular disease
or at least one other risk factor for vascular
disease, were enrolled from 215 centers in
20 countries. There were no A1C or blood
pressure inclusion criteria. Approval for
the trial was obtained from each center’s
institutional review board, and all partic-
ipants provided written informed con-
sent. After a 6-week active run-in period
with fixed-combination perindopril and
indapamide (2 mg/0.625 mg), during
which usual glucose control was contin-
ued, participants were randomly as-
signed, in a factorial design, to continued
perindopril-indapamide (2 mg/0.625 mg
for the first 3 months then 4 mg/1.25 mg
thereafter) or matching placebo and to ei-
ther an intensive glucose control strategy
aiming for an A1C of6.5% or a standard
glucose control strategy (target A1C levels
defined by local guidelines) using a cen-
tral, computer-based randomization ser-
vice. Participants randomly assigned to
intensive glucose control were given gli-
clazide MR (30–120 mg daily) and other
glucose-lowering drugs as required by
their primary physicians (8). Participants
randomly assigned to the standard con-
trol who were using gliclazide MR at
study entry were required to substitute
this with another sulfonylurea, if contin-
ued therapy was required (8).
Outcomes and follow-up
The primary outcomes were a composite
of macrovascular (cardiovascular death,
nonfatal myocardial infarction, or nonfa-
tal stroke) and microvascular (new or
worsening nephropathy or retinopathy)
events, considered jointly and separately
(4,8). The secondary outcomes examined
were death from all causes, cardiovascular
death, major coronary events (death due
to coronary heart disease [including sud-
den death] or nonfatal myocardial infarc-
tion), major cerebrovascular events
(death due to cerebrovascular disease or
nonfatal stroke), new or worsening ne-
phropathy (requirement for renal re-
placement therapy, death from renal
disease, development of macroalbumin-
uria, or a doubling of serum creatinine to
a level of at least 200 mol/l), new onset
of microalbuminuria (urinary albumin-
to-creatinine ratio 30–300 g/mg) and
total renal events (defined post hoc as the
composite of new or worsening nephrop-
athy or new onset of microalbuminuria),
and new or worsening retinopathy. Primary
outcomes and all deaths were reviewed and
validated by an independent end point ad-
judication committee blinded to treatment
allocation (4,8). For the purposes of this
study, the joint effects of randomized treat-
ments were studied after 4.3 years of follow
up, that is, at completion of the blood pres-
sure intervention, although the glucose-
lowering intervention was completed after
an average of 5 years.
Statistical analysis
Differences between randomized groups
in blood pressure and A1C during
follow-up were estimated using linear
mixed models. Annual event rates were
calculated with the person-years method.
Combined treatment effects on study end
points were estimated from unadjusted
Cox proportional hazard models, using
survival time to the first relevant end
point in any individual patient, according
to the principle of intention to treat. Only
the first event of the relevant outcome
type was included in each analysis. Par-
ticipants were censored at their date of
death, date of last visit (for those still alive
at the end of follow-up), or date when last
known to be alive (for those with un-
known vital status). For each outcome,
interactions between treatment effects
were tested by adding interaction terms to
the relevant Cox models and comparing
the likelihood statistics for the models
with and without interaction; this will
thus be termed a test for an additive inter-
action here. However, because Cox mod-
els work on the logarithmic scale, the null
hypothesis being tested is that the joint
effect of the two treatments is the product
of their individual effects, with all effects
measured through hazard ratios (HRs)
(16). All P values were calculated from
two-tailed tests of statistical significance
with a type I error rate of 5%. All analyses
were performed using SAS (version 9.1).
RESULTS
Baseline characteristics
The four treatment groups were well bal-
anced for a range of baseline characteris-
tics (Table 1). In all four groups, 32% of
participants had a history of major macro-
vascular disease and 10% had a history of
major microvascular disease. Mean dura-
tion of diabetes was 8 years, and mean entry
A1C and blood pressure were 7.5% and
145/81 mmHg, respectively (Table 1).
Characteristics during follow-up
At the end of 4.3 years of follow-up, use
of concomitant treatment was similar
among the four treatment groups (sup-
plementary Table, available in an online
appendix at http://care.diabetesjournals.
org/cgi/content/full/dc09-0959/DC1). Over
the duration of 4.3 years, blood pressure
was reduced by an average  SEM of
7.1  0.3 mmHg systolic and 2.9  0.2
mmHg diastolic blood pressure in pa-
tients assigned to joint treatment com-
pared with those assigned to neither
treatment (P  0.001). Similarly, A1C
was reduced by 0.61  0.02% after 4.3
years follow-up in patients assigned to
joint treatment compared with those as-
signed to neither treatment (P  0.001).
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Joint effects of routine blood
pressure lowering and intensive
glucose control
The HRs for the combination of blood
pressure lowering with perindopril-
indapamide and intensive glucose control
with gliclazide MR and for either active
treatment compared with those for placebo
and standard glucose control are shown for
all clinical outcomes in Table 2. There was
no interaction between the effects of routine
blood pressure lowering and intensive glu-
cose control for any of the prespecified clin-
ical end points (all P 0.1), indicating that
the effects of these two interventions were
independent.
A total of 1,799 participants had a
major macrovascular or microvascular
event during follow-up: 431 (15.5%) in
the joint treatment group and 498
(17.9%) in the group that received neither
active intervention, a relative risk reduc-
tion of 15% (95% CI 3–25%, P  0.02).
Compared with neither active interven-
tion, combined treatment reduced the
risk of microvascular events by 19% (3–
32%, P  0.02) but had no significant
effect on the incidence of macrovascular
events (8% [10 to 23%], P  0.35).
A total of 2,683 participants had a
major renal event during follow-up: 590
(21.2%) in the joint treatment group and
777 (27.9%) in the group that received
neither active intervention. Compared
with neither active intervention, com-
bined treatment reduced the risk of all
renal events by 28% (95% CI 19–35%,
P  0.0001), which included a 33% re-
duction in the risk of new or worsening
nephropathy (12–50%, P  0.005), a
54% reduction in the risk of new onset of
macroalbuminuria (35– 68%, P 
0.0001), and a 25% reduction in the risk
of new onset of microalbuminuria (16–
33%, P  0.001). The effects of each in-
tervention on all renal events were
intermediate between those of joint treat-
ment and neither active intervention.
When considered separately, the effects
of the two interventions were additive on
the log scale, and the effect of each inter-
vention was not altered by the other treat-
ment (Fig. 1).
A total of 879 participants died dur-
ing follow-up: 198 (7.1%) in the joint
treatment group and 240 (8.6%) in the
group that received neither active inter-
vention. Compared with those in neither
active intervention, those allocated to
joint treatment had a significantly lower
annual mortality rate (relative risk reduc-
tion 18% [95% CI 1–32%], P  0.04)
with the effects of the two treatments be-
ing independent of each other (Fig. 2).
CONCLUSIONS— The ADVANCE
trial has reported the separate beneficial
effects of routine blood pressure lowering
with perindopril-indapamide and inten-
sive glucose control with a gliclazide MR–
based regimen on a range of vascular
complications in patients with type 2 di-
abetes (4,8). In the present analyses we
show that the combined effect of both
treatments was at least as great as the ef-
fect of either treatment alone for all clini-
cal outcomes and appeared to be greater
for some. This finding was most clearly
apparent where both blood pressure low-
ering and intensive glucose control had
separate significant beneficial effects, as
Table 1—Characteristics of randomized participants at baseline
Characteristic
Intensive glucose and
perindopril-indapamide
Standard glucose and
perindopril-indapamide
Intensive glucose
and placebo
Standard glucose
and placebo
n 2,783 2,786 2,788 2,783
Age (years) 65.8  6.3 65.8  6.4 65.7  6.5 65.8  6.4
Female sex 1,198 (43.0) 1,168 (41.9) 1,181 (42.4) 1,188 (42.7)
Age when diabetes first diagnosed (years) 57.8  8.5 57.9  8.9 57.8  8.7 57.8  8.8
Diabetes duration (years) 8.0  6.4 8.0  6.4 7.8  6.3 8.0  6.3
Prior vascular disease
History of major macrovascular disease 896 (32.2) 902 (32.4) 898 (32.2) 894 (32.1)
History of myocardial infarction 339 (12.2) 339 (12.2) 329 (11.8) 327 (11.7)
History of stroke 254 (9.1) 248 (8.9) 261 (9.4) 259 (9.3)
History of major microvascular disease 281 (10.1) 287 (10.3) 288 (10.3) 296 (10.6)
History of macroalbuminuria 94 (3.5) 103 (3.9) 93 (3.5) 111 (4.2)
History of microvascular eye disease 195 (7.0) 194 (7.0) 206 (7.4) 198 (7.1)
History of microalbuminuria 726 (27.4) 715 (26.9) 711 (26.7) 710 (26.7)
Blood glucose control
A1C concentration (%) 7.5  1.6 7.6  1.6 7.5  1.6 7.5  1.5
Fasting blood glucose (mmol/l) 8.6  2.8 8.5  2.8 8.5  2.7 8.4  2.8
Other major risk factors
Systolic blood pressure (mmHg) 145.3  22.1 144.8  21.6 144.6  21.3 145.3  21.2
Diastolic blood pressure (mmHg) 80.9  11.1 80.5  11.0 80.6  11.0 80.5  10.7
Currently treated hypertension 1,909 (68.6) 1,893 (67.9) 1,907 (68.4) 1,946 (69.9)
Serum total cholesterol (mmol/l) 5.2  1.2 5.2  1.2 5.2  1.2 5.2  1.2
Serum LDL cholesterol (mmol/l) 3.1  1.0 3.1  1.0 3.1  1.0 3.1  1.0
Serum HDL cholesterol (mmol/l) 1.3  0.3 1.3  0.4 1.3  0.4 1.3  0.3
Serum triglycerides (mmol/l) 1.6 (1.2–2.3) 1.6 (1.2–2.3) 1.6 (1.2–2.4) 1.7 (1.2–2.3)
Urinary albumin-to-creatinine ratio (g/mg) 15 (7–40) 15 (7–40) 15 (7–39) 14 (7–40)
BMI (kg/m2) 28.4  5.1 28.3  5.3 28.4  5.2 28.3  5.1
Current smoking 387 (13.9) 346 (12.4) 406 (14.6) 411 (14.8)
Data are means  SD, n (%), or median (interquartile range).
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was observed for all renal events and the
components of new or worsening ne-
phropathy, new onset of microalbumin-
uria, and new onset of macroalbuminuria
(Table 2). Where a separately significant
beneficial effect was observed only for
blood pressure lowering (as for all-cause
mortality and cardiovascular death), the
addition of intensive glucose control did
not negate that effect. In fact, for all-cause
mortality (Table 2, Fig. 2) and cardiovas-
cular death (Table 2), the estimates of the
effect size for the joint intervention were
slightly greater than they were for blood
pressure lowering alone. These findings
provide considerable reassurance that the
widely used clinical approach of joint
management of blood pressure and glu-
cose in patients with type 2 diabetes is
both appropriate and effective.
Our findings support and strengthen
those of the UKPDS (14) and provide fur-
ther evidence for the benefits of a multi-
factorial treatment approach that includes
blood pressure lowering and intensive
glucose control in patients with type 2
diabetes. The previously reported bene-
fits of multifactorial risk management in
the STENO 2 study were obtained
through a combination of optimal blood
pressure, glucose control, lipid modifica-
tion, and antiplatelet therapy, although
only 20% of participants achieved A1C
levels of 7% (11). Our data show that
intensification of glycemic control to
achieve A1C levels of 6.5% augments
the benefits obtained with blood pres-
sure–lowering treatment, particularly
with respect to renal events. Our study
also shows that such an approach has
benefits not only for individuals with type
2 diabetes who also have hypertension
Table 2—Joint effects of routine blood pressure lowering and intensive glucose control on all clinical outcomes
Randomized treatments
Pinteraction
Intensive glucose and
perindopril-indapamide
Standard glucose and
perindopril-indapamide
Intensive glucose
and placebo
Standard glucose
and placebo
n 2,783 2,786 2,788 2,783
Primary outcomes
Combined major microvascular
and macrovascular events
No. events 431 430 440 498
HR (95% CI) 0.85 (0.75–0.97) 0.85 (0.74–0.96) 0.87 (0.77–0.99) 1.00 (reference) 0.13
Major microvascular events
No. events 213 226 217 260
HR (95% CI) 0.81 (0.68–0.97) 0.85 (0.72–1.02) 0.83 (0.69–0.99) 1.00 (reference) 0.32
Major macrovascular events
No. events 246 234 255 265
HR (95% CI) 0.92 (0.77–1.10) 0.87 (0.73–1.04) 0.96 (0.81–1.14) 1.00 (reference) 0.44
Other outcomes
Death from any cause
No. events 198 210 231 240
HR (95% CI) 0.82 (0.68–0.99) 0.87 (0.72–1.04) 0.96 (0.80–1.15) 1.00 (reference) 0.90
Death from cardiovascular causes
No. events 104 107 121 136
HR (95% CI) 0.76 (0.59–0.98) 0.78 (0.60–1.00) 0.89 (0.70–1.14) 1.00 (reference) 0.62
Major coronary heart events
No. events 133 132 139 155
HR (95% CI) 0.92 (0.77–1.10) 0.87 (0.73–1.04) 0.90 (0.71–1.13) 1.00 (reference) 0.47
Major cerebrovascular events
No. events 111 104 111 107
HR (95% CI) 1.03 (0.79–1.35) 0.96 (0.73–1.26) 1.03 (0.79–1.35) 1.00 (reference) 0.85
All renal events
No. events 590 630 686 777
HR (95% CI) 0.72 (0.65–081) 0.77 (0.69–0.85) 0.88 (0.79–0.97) 1.00 (reference) 0.33
New or worsening nephropathy
No. events 81 100 96 120
HR (95% CI) 0.67 (0.50–0.88) 0.82 (0.63–1.07) 0.80 (0.61–1.05) 1.00 (reference) 0.93
New or worsening retinopathy
No. events 147 142 133 153
HR (95% CI) 0.96 (0.76–1.20) 0.92 (0.73–1.16) 0.86 (0.69–1.09) 1.00 (reference) 0.27
New onset of microalbuminuria
No. events 525 542 605 673
HR (95% CI) 0.75 (0.67–0.84) 0.77 (0.68–0.86) 0.90 (0.80–100) 1.00 (reference) 0.29
New onset of macroalbuminuria
No. events 44 74 73 95
HR (95% CI) 0.46 (0.32–0.65) 0.77 (0.56–1.04) 0.77 (0.57–1.04) 1.00 (reference) 0.30
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(14) or microalbuminuria (11) but for a
much broader cross-section of the popu-
lation with type 2 diabetes.
The substantial renal benefits ob-
served in both arms of the ADVANCE trial
and magnified in the group receiving both
interventions may also translate into fu-
ture cardiovascular benefits. Elevated lev-
els of albuminuria have clearly been
demonstrated to be a risk factor for car-
diovascular disease in patients with type 2
diabetes (17), with current screening
strategies aimed to identify affected pa-
tients so that appropriate preventive treat-
ments may be introduced. Recent studies
have suggested that treatment of albumin-
uria per se may reduce cardiovascular
events (18). Long-term follow-up of the
UKPDS study (19) has also demonstrated
that the cardiovascular and mortality ben-
efits of intensive glucose control emerge
over time. The combined treatment strat-
egy used in ADVANCE would therefore
be anticipated to further reduce cardio-
vascular risk in the long term.
In the ACCORD study, intensive glu-
cose control increased the risk of death
(9). However, the overall mortality rate
was much lower than predicted, probably
as a consequence of the factorial study de-
sign that included intensive blood pres-
sure– and lipid-lowering interventions.
Our analyses provide no evidence of such
an increase in mortality either in the glu-
cose-lowering arm of the ADVANCE trial
as reported previously (8) or in the
present analyses. On the contrary, the
combination of both active interventions
compared with neither active interven-
tion significantly reduced the risk of all-
cause and cardiovascular mortality. There
was also no indication that the benefits of
routine blood pressure lowering were off-
set by the intensive glucose control inter-
vention. If anything, the magnitude of
risk reduction was somewhat greater in
the group receiving both interventions
than that observed in the group receiving
routine blood pressure lowering alone. It
is noteworthy that the intensive glucose
control strategies applied in ADVANCE
and in ACCORD differed substantially in
the way the glucose target was achieved
(8,9). Our results indicate that intensive
glucose control can be implemented
safely through a conventional approach,
using the gliclazide MR–based regimen
Figure 1—Relative effects of routine blood pressure–lowering and intensive glucose control strategy on all prespecified renal events. The effects of
treatment (HRs) were estimated from unadjusted Cox proportional hazards models that used all available data at 4.3 years of follow-up. The
diamonds incorporate the point estimates, represented by the vertical dashed lines, and the 95% CIs of the overall effects within categories; for
subcategories, black squares represent point estimates (with the area of each square proportional to the inverse variance of each estimate), and
horizontal lines represent 95% CIs. The HRs and relative risk reductions are given for intensive glucose control compared with standard glucose
control in the blood pressure–lowering arm and for perindopril-indapamide (Per-Ind) compared with placebo in the glucose-lowering arm.
ADVANCE: blood pressure and glucose control
2072 DIABETES CARE, VOLUME 32, NUMBER 11, NOVEMBER 2009 care.diabetesjournals.org
and stepwise increase in oral agents and,
eventually, basal insulin (8).
Although we found no evidence for
an interaction between the blood pres-
sure– and glucose-lowering interventions
for any of the outcomes, we are unable to
fully exclude the presence of an interac-
tion, particularly for some of the less com-
mon outcomes. Exclusion of any
interaction between the two interventions
of the ADVANCE trial would have re-
quired a sample size 4 times as large to be
adequately powered (20). The absence of
an interaction is further supported by ob-
servational data demonstrating that asso-
ciations of blood pressure levels and
measures of glycemic control with the
risks of mortality and coronary heart dis-
ease in patients with type 2 diabetes are
independent and additive (14,21,22).
When the treatments were not dem-
onstrated to have separate significant ben-
efits, as for macrovascular events, such
effects were also not observed with com-
bined treatment. One possible explana-
tion is the relatively short length of study
follow-up. This may particularly influ-
ence the effect of the glucose-lowering
strategy for which the rate of macrovascu-
lar events only began to diverge in the last
12 months of the average 5-year period of
follow-up, whereas the present analyses
were limited to 4.3 years of follow up (8).
The resultant loss of a large number of
events that occurred with prolongation of
the randomized glucose intervention
therefore limited the statistical power to
detect significant effects. In addition, the
lower-than-anticipated event rates, possi-
bly reflecting the comprehensive back-
ground management of cardiovascular
risk in both arms (4,8), and less-than-
projected separation in A1C between the
glucose treatment groups may have fur-
ther reduced the ability to detect an effect
reliably. The recent report from the 10-
year post-trial follow-up of the UKPDS
cohort of significant long-term benefits
observed with intensive glucose control
for macrovascular events (19) suggests
that the ADVANCE trial may have required
much longer follow-up to demonstrate
clear benefits of intensive glucose (8) or
combined treatment for this outcome.
In summary, the ADVANCE trial has
demonstrated that a combined approach
of routine blood pressure lowering and
intensive glucose control resulted in sub-
stantial reductions in major renal events
and all-cause death. For the major renal
outcomes, the separately significant ben-
eficial effects of the two interventions
were additive. This suggests that the mul-
tifactorial management of type 2 diabetes
should incorporate routine blood pres-
sure lowering and more intensive glucose
control to reduce the burden of adverse
clinical sequelae in individuals with es-
tablished diabetes.
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